| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 595.177 | 609.800 | 612.470 | 589.294 | 590.175 | 681.856 | 717.014 | 661.766 | 579.552 | 549.010 |
| Total Income - EUR | 630.165 | 644.599 | 641.131 | 619.029 | 617.945 | 711.248 | 741.365 | 706.494 | 628.801 | 572.988 |
| Total Expenses - EUR | 552.528 | 565.287 | 577.558 | 576.338 | 577.294 | 723.745 | 693.571 | 655.506 | 597.215 | 551.303 |
| Gross Profit/Loss - EUR | 77.637 | 79.312 | 63.574 | 42.691 | 40.651 | -12.496 | 47.794 | 50.988 | 31.586 | 21.685 |
| Net Profit/Loss - EUR | 64.575 | 65.595 | 52.132 | 36.501 | 34.471 | -19.117 | 40.380 | 43.945 | 25.335 | 18.643 |
| Employees | 4 | 5 | 4 | 3 | 4 | 4 | 5 | 5 | 5 | 5 |
Check the financial reports for the company - Lyrafarm 2003 Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 46.085 | 44.249 | 60.465 | 49.742 | 43.175 | 33.632 | 22.196 | 10.901 | 1.503 | 0 |
| Current Assets | 55.944 | 60.795 | 52.789 | 64.383 | 73.677 | 85.775 | 70.935 | 76.765 | 91.953 | 77.562 |
| Inventories | 39.245 | 44.780 | 37.949 | 39.629 | 44.586 | 62.175 | 65.075 | 71.264 | 79.149 | 63.431 |
| Receivables | 371 | 20 | 8 | 8 | 3.711 | 208 | 0 | 0 | 3.765 | 3.751 |
| Cash | 16.328 | 15.994 | 14.832 | 24.747 | 25.380 | 23.391 | 5.859 | 5.501 | 9.039 | 10.380 |
| Shareholders Funds | 60.989 | 65.640 | 52.176 | 36.544 | 34.513 | -19.076 | 21.749 | 43.985 | 25.376 | 18.683 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 41.041 | 39.404 | 61.079 | 77.581 | 82.339 | 138.482 | 71.382 | 43.681 | 68.081 | 58.879 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Lyrafarm 2003 Srl